Brufsky (2003), in a phase II study of docetaxel, carboplatin, and trastuzumab in 38 patients, observed that out of those patients progressing on therapy 50% developed CNS disease. The rate of BM is particularly high in patients deriving Sinomenine hydrochloride systemic benefit from trastuzumab: 18 out of 23 (78%) patients who developed BM had SD […]